References
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, & Dinarello CA
(2020). Interleukin-1 and the Inflammasome as Therapeutic Targets in
Cardiovascular Disease. Circ Res 126: 1260-1280.
Alessi MC, Cenac N, Si-Tahar M, & Riteau B (2017). FPR2: A Novel
Promising Target for the Treatment of Influenza. Front Microbiol
8: 1719.
Almond MH, Edwards MR, Barclay WS, & Johnston SL (2013). Obesity and
susceptibility to severe outcomes following respiratory viral infection.
Thorax 68: 684-686.
Bauer RN, Brighton LE, Mueller L, Xiang Z, Rager JE, Fry RC, et
al. (2012). Influenza enhances caspase-1 in bronchial epithelial cells
from asthmatic volunteers and is associated with pathogenesis. J Allergy
Clin Immunol 130: 958-967 e914.
Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, et
al. (2011). Azithromycin inhibits macrophage interleukin-1beta
production through inhibition of activator protein-1 in
lipopolysaccharide-induced murine pulmonary neutrophilia. Int
Immunopharmacol 11: 424-434.
Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, & Perretti M
(2011). Evidence for an anti-inflammatory loop centered on
polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4
receptor and operative in the inflamed microvasculature. J Immunol
186: 4905-4914.
Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower
RJ, et al. (2013). A vasculo-protective circuit centered on
lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine
microcirculation. Blood 122: 608-617.
Cahill CM, & Rogers JT (2008). Interleukin (IL) 1beta induction of IL-6
is mediated by a novel phosphatidylinositol 3-kinase-dependent
AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol
Chem 283: 25900-25912.
Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. (2020). Obesity
and COVID-19 Severity in a Designated Hospital in Shenzhen, China.
Diabetes Care.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020). A
Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe
Covid-19. N Engl J Med 382: 1787-1799.
Chen W, Zhao M, Zhao S, Lu Q, Ni L, Zou C, et al. (2017).
Activation of the TXNIP/NLRP3 inflammasome pathway contributes to
inflammation in diabetic retinopathy: a novel inhibitory effect of
minocycline. Inflamm Res 66: 157-166.
Chen X, Wang N, Zhu Y, Lu Y, Liu X, & Zheng J (2017). The Antimalarial
Chloroquine Suppresses LPS-Induced NLRP3 Inflammasome Activation and
Confers Protection against Murine Endotoxic Shock. Mediators Inflamm
2017: 6543237.
Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C,
et al. (2020). Baricitinib counteracts metaflammation, thus protecting
against diet-induced metabolic abnormalities in mice. Mol Metab
39: 101009.
Cure E, Kucuk A, & Cumhur Cure M (2020). Cyclosporine therapy in
cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int
40: 1177-1179.
Dinarello CA (2009). Immunological and inflammatory functions of the
interleukin-1 family. Annu Rev Immunol 27: 519-550.
Dixon AE, & Peters U (2018). The effect of obesity on lung function.
Expert Rev Respir Med 12: 755-767.
Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et
al. (2010). Anti-inflammatory role of the murine formyl-peptide
receptor 2: ligand-specific effects on leukocyte responses and
experimental inflammation. J Immunol 184: 2611-2619.
Fink SL, & Cookson BT (2005). Apoptosis, pyroptosis, and necrosis:
mechanistic description of dead and dying eukaryotic cells. Infect Immun
73: 1907-1916.
Furuya MY, Asano T, Sumichika Y, Sato S, Kobayashi H, Watanabe H,
et al. (2018). Tofacitinib inhibits granulocyte-macrophage
colony-stimulating factor-induced NLRP3 inflammasome activation in human
neutrophils. Arthritis Res Ther 20: 196.
Galvao I, de Carvalho RVH, Vago JP, Silva ALN, Carvalho TG, Antunes
MM, et al. (2020). The role of annexin A1 in the modulation of
the NLRP3 inflammasome. Immunology 160: 78-89.
Grant RW, & Dixit VD (2013). Mechanisms of disease: inflammasome
activation and the development of type 2 diabetes. Front Immunol
4: 50.
Green WD, & Beck MA (2017). Obesity Impairs the Adaptive Immune
Response to Influenza Virus. Ann Am Thorac Soc 14: S406-S409.
Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, &
Zlabinger GJ (2015). Azithromycin inhibits IL-1 secretion and
non-canonical inflammasome activation. Sci Rep 5: 12016.
Guan M, Ma H, Fan X, Chen X, Miao M, & Wu H (2020). Dexamethasone
alleviate allergic airway inflammation in mice by inhibiting the
activation of NLRP3 inflammasome. Int Immunopharmacol 78:106017.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (2020).
Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J
Med 382: 1708-1720.
Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, et al.(2004). Chloroquine protects mice from challenge with CpG ODN and LPS by
decreasing proinflammatory cytokine release. Int Immunopharmacol
4: 223-234.
Hotamisligil GS (2017). Inflammation, metaflammation and immunometabolic
disorders. Nature 542: 177-185.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020).
Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet 395: 497-506.
Huttunen R, & Syrjanen J (2010). Obesity and the outcome of infection.
Lancet Infect Dis 10: 442-443.
Huttunen R, & Syrjanen J (2013). Obesity and the risk and outcome of
infection. Int J Obes (Lond) 37: 333-340.
Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H,
Tsoumani M, et al. (2019). Differential effects of inhibition of
interleukin 1 and 6 on myocardial, coronary and vascular function. Clin
Res Cardiol 108: 1093-1101.
Iyer SS, He Q, Janczy JR, Elliott EI, Zhong Z, Olivier AK, et al.(2013). Mitochondrial cardiolipin is required for Nlrp3 inflammasome
activation. Immunity 39: 311-323.
Jia X, Liu B, Bao L, Lv Q, Li F, Li H, et al. (2018). Delayed
oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced
severe lung injury correlated with repressed NLRP3 inflammasome
activation and inflammatory cell infiltration. PLoS Pathog 14:e1007428.
Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J, et al. (2020). Two
Things about COVID-19 Might Need Attention. Preprints.
Jorgensen I, Zhang Y, Krantz BA, & Miao EA (2016). Pyroptosis triggers
pore-induced intracellular traps (PITs) that capture bacteria and lead
to their clearance by efferocytosis. J Exp Med 213: 2113-2128.
Karlsson EA, Sheridan PA, & Beck MA (2010). Diet-induced obesity
impairs the T cell memory response to influenza virus infection. J
Immunol 184: 3127-3133.
Kelley N, Jeltema D, Duan Y, & He Y (2019). The NLRP3 Inflammasome: An
Overview of Mechanisms of Activation and Regulation. Int J Mol Sci 20.
Ko JH, Yoon SO, Lee HJ, & Oh JY (2017). Rapamycin regulates macrophage
activation by inhibiting NLRP3 inflammasome-p38 MAPK-NFkappaB pathways
in autophagy- and p62-dependent manners. Oncotarget 8:40817-40831.
Kopitar-Jerala N (2017). The Role of Interferons in Inflammation and
Inflammasome Activation. Front Immunol 8: 873.
Kwong JC, Campitelli MA, & Rosella LC (2011). Obesity and respiratory
hospitalizations during influenza seasons in Ontario, Canada: a cohort
study. Clin Infect Dis 53: 413-421.
Latz E, & Duewell P (2018). NLRP3 inflammasome activation in
inflammaging. Semin Immunol 40: 61-73.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois
F, et al. (2020). Obesity in patients younger than 60 years is a
risk factor for Covid-19 hospital admission.
. Clin Infect Dis
Lippi G, Mattiuzzi C, Bovo C, & Plebani M (2020). Current laboratory
diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed
91: 137-145.
Lopategi A, Flores-Costa R, Rius B, Lopez-Vicario C, Alcaraz-Quiles J,
Titos E, et al. (2019). Frontline Science: Specialized
proresolving lipid mediators inhibit the priming and activation of the
macrophage NLRP3 inflammasome. J Leukoc Biol 105: 25-36.
Lopez-Castejon G, & Pelegrin P (2012). Current status of inflammasome
blockers as anti-inflammatory drugs. Expert Opin Investig Drugs
21: 995-1007.
Lu Y, Xiao G, & Luo W (2016). Minocycline Suppresses NLRP3 Inflammasome
Activation in Experimental Ischemic Stroke. Neuroimmunomodulation
23: 230-238.
Lupfer C, Malik A, & Kanneganti TD (2015). Inflammasome control of
viral infection. Curr Opin Virol 12: 38-46.
Machado MG, Tavares LP, Souza GVS, Queiroz-Junior CM, Ascencao FR, Lopes
ME, et al. (2020). The Annexin A1/FPR2 pathway controls the
inflammatory response and bacterial dissemination in experimental
pneumococcal pneumonia. FASEB J 34: 2749-2764.
Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, & Guimaraes
MZ (2011). Colchicine inhibits cationic dye uptake induced by ATP in
P2X2 and P2X7 receptor-expressing cells: implications for its
therapeutic action. Br J Pharmacol 163: 912-926.
Mastrocola R, Aragno M, Alloatti G, Collino M, Penna C, & Pagliaro P
(2018). Metaflammation: Tissue-Specific Alterations of the NLRP3
Inflammasome Platform in Metabolic Syndrome. Curr Med Chem 25:1294-1310.
Mastrocola R, Collino M, Penna C, Nigro D, Chiazza F, Fracasso V,
et al. (2016). Maladaptive Modulations of NLRP3 Inflammasome and
Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of
Myocardial Ischemia/Reperfusion Injury in Mice. Oxid Med Cell Longev
2016: 3480637.
Milner JJ, & Beck MA (2012). The impact of obesity on the immune
response to infection. Proc Nutr Soc 71: 298-306.
Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald
KA, et al. (2013). Nitric oxide controls the immunopathology of
tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of
IL-1beta. Nat Immunol 14: 52-60.
Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van
Crevel R, van de Veerdonk FL, et al. (2020). Trained Immunity: a
Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2
Infection. Cell 181: 969-977.
Nidorf SM, Eikelboom JW, & Thompson PL (2014). Targeting cholesterol
crystal-induced inflammation for the secondary prevention of
cardiovascular disease. J Cardiovasc Pharmacol Ther 19: 45-52.
Norling LV, Dalli J, Flower RJ, Serhan CN, & Perretti M (2012).
Resolvin D1 limits polymorphonuclear leukocyte recruitment to
inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc
Biol 32: 1970-1978.
O’Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi
S, et al. (2019). Bruton’s Tyrosine Kinase Inhibition Attenuates
the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Front Immunol 10: 2129.
Otani K, Watanabe T, Shimada S, Takeda S, Itani S, Higashimori A,
et al. (2016). Colchicine prevents NSAID-induced small intestinal
injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep
6: 32587.
Perretti M, & D’Acquisto F (2009). Annexin A1 and glucocorticoids as
effectors of the resolution of inflammation. Nat Rev Immunol 9:62-70.
Pinar AA, Scott TE, Huuskes BM, Tapia Caceres FE, Kemp-Harper BK, &
Samuel CS (2020). Targeting the NLRP3 inflammasome to treat
cardiovascular fibrosis. Pharmacol Ther 209: 107511.
Potenza MA, Nacci C, De Salvia MA, Sgarra L, Collino M, & Montagnani M
(2017). Targeting endothelial metaflammation to counteract diabesity
cardiovascular risk: Current and perspective therapeutic options.
Pharmacol Res 120: 226-241.
Powell N, Lo JW, Biancheri P, Vossenkamper A, Pantazi E, Walker
AW, et al. (2015). Interleukin 6 Increases Production of
Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With
Chronic Intestinal Inflammation. Gastroenterology 149: 456-467
e415.
Ratajczak MZ, & Kucia M (2020). SARS-CoV-2 infection and overactivation
of Nlrp3 inflammasome as a trigger of cytokine ”storm” and risk factor
for damage of hematopoietic stem cells. Leukemia.
Rayamajhi M, Zhang Y, & Miao EA (2013). Detection of pyroptosis by
measuring released lactate dehydrogenase activity. Methods Mol Biol
1040: 85-90.
Ruan Q, Yang K, Wang W, Jiang L, & Song J (2020). Clinical predictors
of mortality due to COVID-19 based on an analysis of data of 150
patients from Wuhan, China. Intensive Care Med 46(5): 846-848.
Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini
G, et al. (2020). COVID-19, cytokines and immunosuppression: what
can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol
38: 337-342.
Serhan CN, Chiang N, & Dalli J (2015). The resolution code of acute
inflammation: Novel pro-resolving lipid mediators in resolution. Semin
Immunol 27: 200-215.
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel
A, et al. (2020). Lille Intensive Care COVID-19 and Obesity study
group. High prevalence of obesity in severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. .
Obesity (Silver Spring).
Singh AK, Gupta R, Ghosh A, & Misra A (2020). Diabetes in COVID-19:
Prevalence, pathophysiology, prognosis and practical considerations.
Diabetes Metab Syndr 14: 303-310.
Sodhi M, & Etminan M (2020). Therapeutic Potential for Tetracyclines in
the Treatment of COVID-19. Pharmacotherapy 40: 487-488.
Sun NN, Yu CH, Pan MX, Zhang Y, Zheng BJ, Yang QJ, et al. (2017).
Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced
NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts.
Sci Rep 7: 14369.
Tack CJ, Stienstra R, Joosten LA, & Netea MG (2012). Inflammation links
excess fat to insulin resistance: the role of the interleukin-1 family.
Immunol Rev 249: 239-252.
Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, et al. (2018).
Hydroxychloroquine attenuates renal ischemia/reperfusion injury by
inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death
Dis 9: 351.
Tschop MH, & DiMarchi RD (2012). Outstanding Scientific Achievement
Award Lecture 2011: defeating diabesity: the case for personalized
combinatorial therapies. Diabetes 61: 1309-1314.
Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt
RL, et al. (2011). The NLRP3 inflammasome instigates
obesity-induced inflammation and insulin resistance. Nat Med
17: 179-188.
Wang Y, Liu X, Shi H, Yu Y, Yu Y, Li M, et al. (2020). NLRP3
inflammasome, an immune-inflammatory target in pathogenesis and
treatment of cardiovascular diseases. Clin Transl Med 10:91-106.
Wanjalla CN, McDonnell WJ, Barnett L, Simmons JD, Furch BD, Lima
MC, et al. (2019). Adipose Tissue in Persons With HIV Is Enriched
for CD4(+) T Effector Memory and T Effector Memory RA(+) Cells, Which
Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With
Increasing Glucose Intolerance. Front Immunol 10: 408.
Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B,
et al. (2008). Feeding our immune system: impact on metabolism. Clin
Dev Immunol 2008: 639803.
Wu R, Liu X, Yin J, Wu H, Cai X, Wang N, et al. (2018). IL-6
receptor blockade ameliorates diabetic nephropathy via inhibiting
inflammasome in mice. Metabolism 83: 18-24.
Xu Y, Ma LL, Zhou C, Zhang FJ, Kong FJ, Wang WN, et al. (2013).
Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion
injury and refractory to sevoflurane-induced protection. PLoS One
8: e76652.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. (2020).
Pathological findings of COVID-19 associated with acute respiratory
distress syndrome. Lancet Respir Med 8: 420-422.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, & Zhou Q (2020). Structural basis
for the recognition of SARS-CoV-2 by full-length human ACE2. Science
367: 1444-1448.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. (2020). Clinical
course and outcomes of critically ill patients with SARS-CoV-2 pneumonia
in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med 8: 475-481.
Yang Y, Wang H, Kouadir M, Song H, & Shi F (2019). Recent advances in
the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell
Death Dis 10: 128.
Yap JKY, Moriyama M, & Iwasaki A (2020). Inflammasomes and Pyroptosis
as Therapeutic Targets for COVID-19. J Immunol.
Zhang X, Zhang G, Ren Y, Lan T, Li D, Tian J, et al. (2018).
Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo. Eur
J Pharmacol 834: 288-294.
Zhao C, & Zhao W (2020). NLRP3 Inflammasome-A Key Player in Antiviral
Responses. Front Immunol 11: 211.
Zhao M, Bai M, Ding G, Zhang Y, Huang S, Jia Z, et al. (2018).
Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte
Injury and Mitochondrial Dysfunction. Kidney Dis (Basel) 4:83-94.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical
course and risk factors for mortality of adult inpatients with COVID-19
in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062.
Zuurbier C, Abbate A, Cabrera-Fuentes H, Cohen M, Collino M, De Kleijn
D, et al. (2019). Innate immunity as a target for acute
cardioprotection. . Cardiovasc Res 115: 1131-1142.